Managed Markets

Five things for pharma marketers to know: Monday, May 4

Five things for pharma marketers to know: Monday, May 4

Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Top 3 formulary access takeaways for pharma

Top 3 formulary access takeaways for pharma

Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Rite Aid buys PBM EnvisionRx for $2B

In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.

Demonstrating the Special Value in Specialty Therapeutics

Demonstrating the Special Value in Specialty Therapeutics

Five things for pharma marketers to know: Thursday, January 29

Five things for pharma marketers to know: Thursday, January 29

Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.

Five things for pharma marketers to know: Friday, January 23

Five things for pharma marketers to know: Friday, January 23

Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.

AbbVie to discount HCV drugs for state HIV programs

A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.